TY - JOUR
T1 - Adult congenital heart disease and pulmonary arterial hypertension
T2 - The texas adult congenital heart program experience
AU - Franklin, Wayne J.
AU - Parekh, Dhaval R.
AU - Safdar, Zeenat
PY - 2011/11/1
Y1 - 2011/11/1
N2 - Congenital heart disease (CHD) is a common structural defect of the heart or major blood vessels. Patients with adult congenital heart disease (ACHD) have medical needs that are distinct from those of pediatric patients with CHD, and the transition into adult health care is important for management of the patient with ACHD. A large proportion of patients with CHD develop diseases and complications associated with the long-term stress of intracardiac shunts. Pulmonary arterial hypertension (PAH) is a significant complication of some CHD lesions. The treatment of these patients remains challenging due to their combined heart and lung disease, and multidisciplinary care is ofen necessitated for a variety of secondary conditions. A number of treatment options are available for the management of PAH associated with CHD, including prostanoids, phosphodiesterase type-5 inhibitors, and endothelin receptor antagonists. This article discusses the diagnosis and management of such ACHD patients with PAH.
AB - Congenital heart disease (CHD) is a common structural defect of the heart or major blood vessels. Patients with adult congenital heart disease (ACHD) have medical needs that are distinct from those of pediatric patients with CHD, and the transition into adult health care is important for management of the patient with ACHD. A large proportion of patients with CHD develop diseases and complications associated with the long-term stress of intracardiac shunts. Pulmonary arterial hypertension (PAH) is a significant complication of some CHD lesions. The treatment of these patients remains challenging due to their combined heart and lung disease, and multidisciplinary care is ofen necessitated for a variety of secondary conditions. A number of treatment options are available for the management of PAH associated with CHD, including prostanoids, phosphodiesterase type-5 inhibitors, and endothelin receptor antagonists. This article discusses the diagnosis and management of such ACHD patients with PAH.
KW - Congenital heart disease
KW - Echocardiography
KW - Endothelin receptor antagonist
KW - Heart failure
KW - Phosphodiesterase type-5 inhibitor
KW - Prostacyclin
KW - Pulmonary arterial hypertension
UR - http://www.scopus.com/inward/record.url?scp=82155171938&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=82155171938&partnerID=8YFLogxK
U2 - 10.3810/pgm.2011.11.2493
DO - 10.3810/pgm.2011.11.2493
M3 - Article
C2 - 22104452
AN - SCOPUS:82155171938
VL - 123
SP - 32
EP - 45
JO - Postgraduate medicine
JF - Postgraduate medicine
SN - 0032-5481
IS - 6
ER -